Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Koffiekamer Terug naar discussie overzicht

Intellia Therapeutics 2024

170 Posts
Pagina: «« 1 ... 4 5 6 7 8 9 | Laatste | Omlaag ↓
  2. Hoger Lager 17 april 2024 16:56

    • Hoger Lager

      Lid sinds: 04 okt 2023

      Laatste bezoek: 27 jul 2024

    • Aanbevelingen

      Ontvangen: 233

      Gegeven: 275

    •    Aantal posts: 359

    quote:

    Rick96 schreef op 16 april 2024 15:48:

    Nog geen beste keuze geweest..
    Door de oorlog zijn de meeste koersen gedaald. Ik zit LT
  3. Hoger Lager 29 april 2024 17:08

    • Hoger Lager

      Lid sinds: 04 okt 2023

      Laatste bezoek: 27 jul 2024

    • Aanbevelingen

      Ontvangen: 233

      Gegeven: 275

    •    Aantal posts: 359

    Intellia Therapeutics, Inc.
    April 29, 2024 7:30 AM EDT
    Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
    Extended follow-up will include safety, kallikrein reduction and attack rate data, including number of patients who continue to be completely attack free through the latest follow-up
    Intellia to host investor webcast on Monday, June 3, at 8 a.m. ET
    CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the acceptance of an oral presentation from the Phase 1 portion of the ongoing NTLA-2002 Phase 1/2 study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, taking place May 31 – June 3 in Valencia, Spain. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for hereditary angioedema (HAE), a rare genetic condition that leads to potentially life-threatening swelling attacks. The presentation will include updated safety and efficacy results from the Phase 1 study across all three dose cohorts (25 mg, 50 mg and 75 mg).

    Presentation Details

    Title: CRISPR-based gene editing of KLKB1 resulted in long-term plasma kallikrein protein reduction and decreased attack rate in patients with hereditary angioedema: Updated results from a phase 1 study

    Session: Breakthroughs in management of Hereditary Angioedema

    Date and Time: Sunday, June 2, 2024, from 8:30 – 10:00 a.m. CET

    Presenter: Hilary Longhurst, M.D., Ph.D., FRCP, FRCPath, Senior Medical Officer at Auckland District Health Board and Honorary Associate Professor at University of Auckland, New Zealand, the trial’s principal investigator in New Zealand
  8. forum rang 5 MisterBlues 3 juni 2024 17:46

    • MisterBlues

      Lid sinds: 09 jan 2020

      Laatste bezoek: 14 jun 2024

    • Aanbevelingen

      Ontvangen: 827

      Gegeven: 626

    •    Aantal posts: 3.331

    Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

    Sun, Jun 2, 2024, 2:00 PM GMT+210 min read
    In this article:

    NTLA
    +9.49%

    Extended follow-up data reaching over two years in the earliest patients dosed reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)

    Eight of 10 patients remain completely attack-free following the 16-week primary observation period through the latest follow-up, including patients with the most severe disease

    Single dose of NTLA-2002 led to a 98% mean reduction in monthly HAE attack rate, with an average follow-up of over 20 months across all patients

    100% of patients who discontinued prophylaxis treatment after NTLA-2002 remain free of chronic prophylaxis treatment

    Favorable safety and tolerability profile observed at all dose levels

    Intellia to host investor webcast on Monday, June 3, at 8 a.m. ET

    CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced long-term data from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for hereditary angioedema (HAE), a rare genetic condition that leads to potentially life-threatening swelling attacks. The data were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, being held May 31 – June 3 in Valencia, Spain.

    “These unprecedented data strengthen our view that NTLA-2002 could be a groundbreaking treatment for people living with hereditary angioedema,” said Intellia President and Chief Executive Officer John Leonard, M.D. “After a single dose of our investigational in vivo CRISPR-based therapy, patients experienced durable elimination of their attacks. We are thrilled to see that the majority of patients have been attack free for over 18 months or longer. These remarkable attack rate reductions have been consistent, even in patients with the most severe symptoms. At the same time, the data from these 10 patients continue to demonstrate a very favorable safety profile. These long-term data provide strong evidence that NTLA-2002 could be a one-time, potential functional cure for this debilitating and life-threatening disease.”

    finance.yahoo.com/news/intellia-thera...
170 Posts
Pagina: «« 1 ... 4 5 6 7 8 9 | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.895
AB InBev 2 5.329
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.580 48.553
ABO-Group 1 19
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 258
Accsys Technologies 22 9.324
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 170
ADMA Biologics 1 33
Adomos 1 126
AdUX 2 457
Adyen 13 17.228
Aedifica 3 871
Aegon 3.257 321.051
AFC Ajax 537 7.031
Affimed NV 2 5.991
ageas 5.843 109.801
Agfa-Gevaert 13 1.913
Ahold 3.536 74.096
Air France - KLM 1.024 34.583
AIRBUS 1 6
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.870
Alfen 14 20.186
Allfunds Group 3 1.274
Almunda Professionals (vh Novisource) 651 4.249
Alpha Pro Tech 1 17
Alphabet Inc. 1 356
Altice 106 51.197
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.485 114.790
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.824 240.909
AMG 965 129.145
AMS 3 73
Amsterdam Commodities 303 6.574
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 400
Antonov 22.632 153.605
Aperam 91 14.392
Apollo Alternative Assets 1 17
Apple 5 339
Arcadis 251 8.650
Arcelor Mittal 2.026 319.268
Archos 1 1
Arcona Property Fund 1 276
arGEN-X 15 9.568
Aroundtown SA 1 201
Arrowhead Research 5 9.395
Ascencio 1 22
ASIT biotech 2 697
ASMI 4.107 38.104
ASML 1.762 81.789
ASR Nederland 19 4.293
ATAI Life Sciences 1 7
Atenor Group 1 352
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 30 10.993
Axsome Therapeutics 1 177
Azelis Group 1 52
Azerion 7 2.734

Beleggingsideeën van onze partners

Macro & Bedrijfsagenda

  1. 29 juli

    1. Heineken Q2-cijfers
    2. Philips, Q2-cijfers
    3. McDonald's Q2-cijfers
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda